Welcome to our dedicated page for Icu Medical news (Ticker: ICUI), a resource for investors and traders seeking the latest updates and insights on Icu Medical stock.
ICU Medical reports news on its global medical-device business in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate-site and home-care settings. Company updates commonly cover quarterly results, fiscal guidance, GAAP and non-GAAP profitability measures, and revenue trends across the Consumables, Infusion Systems and Vital Care product lines.
Recurring announcements also include earnings-call schedules, investor conference participation and business changes that affect reported comparisons, including the completed divestiture of the IV Solutions business. The company’s news flow centers on product-line performance, margin trends, adjusted EBITDA, adjusted diluted earnings per share and management commentary on operating results.
Summary not available.
ICU Medical (Nasdaq: ICUI), a leader in medical product development, has announced its participation in the J.P. Morgan 41st Annual Healthcare Conference in San Francisco from January 9-12, 2023. The company's presentation is scheduled for January 11, 2023, at 1:30 p.m. PST (4:30 p.m. EST) and will be available via a live webcast on its website. ICU Medical specializes in infusion systems and critical care products, aiming to deliver quality and innovation to clinical customers globally. More information can be found on their website.
ICU Medical reported third quarter 2022 revenue of $597.9 million, significantly up from $336.1 million year-over-year. GAAP gross profit rose to $186.4 million but gross margin decreased to 31% from 38%. The firm posted a GAAP net loss of $(13.2) million or $(0.55) per share, compared to a net income of $31.1 million a year earlier. Adjusted diluted EPS was $1.75, down from $2.07. The company reaffirmed its 2022 guidance, estimating a net loss between $(95) million and $(81) million.
ICU Medical (Nasdaq: ICUI) announced its third quarter 2022 earnings release will occur on November 7, 2022, at 4:00 p.m. ET. The conference call is set for 4:30 p.m. ET on the same day. Investors can join the call by dialing (877) 300-8521 and entering conference ID 10171949. A webcast of the call will also be available on the company's website, with a replay option to follow. ICU Medical is renowned for its infusion systems and critical care products used globally in healthcare settings.
ICU Medical, Inc. (Nasdaq:ICUI) has announced that its management will participate in a fireside chat at the Morgan Stanley Annual Global Healthcare Conference on September 12, 2022, at 11:15 a.m. PT (2:15 p.m. ET). The event will be accessible via a live webcast on the company's website, with a replay available afterward. Additionally, one-on-one meetings will also be held on the same day. ICU Medical specializes in infusion systems and critical care products, serving various healthcare settings.
ICU Medical reported strong second quarter results for 2022, with revenues of $561 million, up from $321.7 million year-over-year. GAAP gross profit increased to $167.6 million, but gross margin fell to 30% from 38%. The company incurred a net loss of $7.5 million compared to a profit of $28.4 million in Q2 2021. Adjusted EBITDA rose to $84.7 million, although adjusted earnings per share decreased from $1.88 to $1.37. The company updated its 2022 guidance, lowering adjusted EBITDA expectations to $350-$370 million and adjusted earnings per share to $6.20-$6.80.
ICU Medical, Inc. (Nasdaq:ICUI) announced the timing of its second quarter 2022 earnings release and conference call. The earnings results will be disclosed on August 8, 2022, at approximately 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. Stakeholders can access the call at (877) 300-8521, using conference ID 10169518. A webcast will also be available on the company's website. ICU Medical specializes in infusion systems and critical care products, catering to hospital and home care settings.
ICU Medical reported strong financial results for Q1 2022, with revenue reaching $543.1 million, up $225.1 million from $318.0 million in Q1 2021. GAAP gross profit stood at $168.8 million (31% gross margin) compared to $112.7 million (35% margin) the previous year. However, the company faced a GAAP net loss of $(38.1) million or $(1.61) per share, contrasting with net income of $23.7 million in Q1 2021. Adjusted diluted EPS improved to $1.82, while adjusted EBITDA rose to $84.9 million.
ICU Medical, Inc. (Nasdaq: ICUI) has scheduled its first quarter 2022 earnings release for May 9, 2022, at 4:00 p.m. ET, followed by a conference call at 4:30 p.m. ET. The call will be accessible by phone at (877) 407-3982 and will also be streamed live via the company's website. ICU Medical specializes in infusion systems and critical care products used in various healthcare settings. The company emphasizes its commitment to quality and innovation for clinical customers worldwide.
SAN CLEMENTE, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- ICU Medical, a leader in innovative medical products, will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum on March 22, 2022, at 8:15 a.m. PT (11:15 a.m. ET). The chat will be webcast live on the company's website and will include one-on-one meetings with investors on the same day. ICU Medical is recognized for its infusion systems and critical care products used globally in various healthcare settings.